BBA clinical最新文献

{"title":"Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects","authors":"Yoshihiro Kamada ,&nbsp;Ryota Hashimoto ,&nbsp;Hidenaga Yamamori ,&nbsp;Yuka Yasuda ,&nbsp;Tetsuo Takehara ,&nbsp;Yuko Fujita ,&nbsp;Kenji Hashimoto ,&nbsp;Eiji Miyoshi","doi":"10.1016/j.bbacli.2016.02.004","DOIUrl":"10.1016/j.bbacli.2016.02.004","url":null,"abstract":"<div><h3>Background &amp; aims</h3><p>Blood aspartate aminotransferase (AST) and alanine transaminase (ALT) levels are the most frequently reliable biomarkers of liver injury. Although AST and ALT play central roles in glutamate production as transaminases, peripheral blood levels of AST and ALT have been regarded only as liver injury biomarkers. Glutamate is a principal excitatory neurotransmitter, which affects memory functions in the brain. In this study, we investigated the impact of blood transaminase levels on blood glutamate concentration and memory.</p></div><div><h3>Methods</h3><p>Psychiatrically, medically, and neurologically healthy subjects (n<!--> <!-->=<!--> <!-->514, female/male: 268/246) were enrolled in this study through local advertisements. Plasma amino acids (glutamate, glutamine, glycine, <span>d</span>-serine, and <span>l</span>-serine) were measured using a high performance liquid chromatography system. The five indices, verbal memory, visual memory, general memory, attention/concentration, and delayed recall of the Wechsler Memory Scale-Revised were used to measure memory functions.</p></div><div><h3>Results</h3><p>Both plasma AST and ALT had a significant positive correlation with plasma glutamate levels. Plasma AST and ALT levels were significantly negatively correlated with four of five memory functions, and plasma glutamate was significantly negatively correlated with three of five memory functions. Multivariate analyses demonstrated that plasma AST, ALT, and glutamate levels were significantly correlated with memory functions even after adjustment for gender and education.</p></div><div><h3>Conclusions</h3><p>As far as we know, this is the first report which could demonstrate the impact of blood transaminase levels on blood glutamate concentration and memory functions in human. These findings are important for the interpretation of obesity-induced metabolic syndrome with elevated transaminases and cognitive dysfunction.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2016.02.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54181255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low magnesium is not a significant predictor of hard events in acute myocardial infarction","authors":"Cristina Vassalle,&nbsp;Debora Battaglia,&nbsp;Alessandro Vannucci,&nbsp;Kyriazoula Chatzianagnostou,&nbsp;Patrizia Landi,&nbsp;Caterina Arvia,&nbsp;Clara Carpeggiani","doi":"10.1016/j.bbacli.2016.03.003","DOIUrl":"10.1016/j.bbacli.2016.03.003","url":null,"abstract":"<div><h3>Background</h3><p>Although magnesium (Mg) has recognized cardioprotective properties and hypomagnesemia is common in patients with acute myocardial infarction (AMI), data regarding the role of Mg as prognostic factor for adverse events are scarce, as well as there are conflicting results on the use of Mg as adjuvant therapy in AMI.</p></div><div><h3>Aim</h3><p>To evaluate the role of Mg as predictor for hard events (HE, all cause death, and nonfatal myocardial infarction) in AMI patients.</p></div><div><h3>Design and patients</h3><p>We studied 406 AMI patients (306 males, age: 67<!--> <!-->±<!--> <!-->12<!--> <!-->years, mean<!--> <!-->±<!--> <!-->SD). Patient data were collected from the Institute electronic databank which saves demographic, clinical, instrumental, therapeutical and follow-up data of all patients admitted to our Coronary Unit.</p></div><div><h3>Results</h3><p>During a mean follow-up period of 21<!--> <!-->±<!--> <!-->18<!--> <!-->months, the combined endpoint accounted for 63 HE, 44 (11%) deaths (35 cardiac deaths), 19 (5%) nonfatal MI.</p><p>The multiple regression model identified glycemia as the only independent determinant of Mg in AMI pts. (T value<!--> <!-->=<!--> <!-->−<!--> <!-->2.8, standard coefficient<!--> <!-->=<!--> <!-->−<!--> <!-->0.15, p<!--> <!-->&lt;<!--> <!-->0.01). The Kaplan–Meier survival estimates failed to show a significantly worst outcome in patients presenting low Mg (&lt;<!--> <!-->0.783<!--> <!-->mmol/L, 25th percentile). Aging (&gt;<!--> <!-->67<!--> <!-->years—50th percentile), and ejection fraction (&lt;<!--> <!-->40%) remained as prognostic factors for HE in the adjusted Cox multivariate proportional hazard model (HR<!--> <!-->=<!--> <!-->2.8, 95% CI<!--> <!-->=<!--> <!-->1.6–5, p<!--> <!-->&lt;<!--> <!-->0.001; HR<!--> <!-->=<!--> <!-->3.2, 95% CI<!--> <!-->=<!--> <!-->1.9–5.3 p<!--> <!-->&lt;<!--> <!-->0.001, respectively).</p></div><div><h3>Conclusion</h3><p>The present findings do not support a significant role of low Mg as predictor for HE in AMI.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2016.03.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54181292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects","authors":"Russell H. Swerdlow ,&nbsp;Rebecca Bothwell ,&nbsp;Lewis Hutfles ,&nbsp;Jeffrey M. Burns ,&nbsp;Gregory A. Reed","doi":"10.1016/j.bbacli.2016.03.005","DOIUrl":"10.1016/j.bbacli.2016.03.005","url":null,"abstract":"<div><p>Bioenergetics and bioenergetic-related functions are altered in Alzheimer's disease (AD) subjects. These alterations represent therapeutic targets and provide an underlying rationale for modifying brain bioenergetics in AD-affected persons. Preclinical studies in cultured cells and mice found that administering oxaloacetate (OAA), a Krebs cycle and gluconeogenesis intermediate, enhanced bioenergetic fluxes and upregulated some brain bioenergetic infrastructure-related parameters. We therefore conducted a study to provide initial data on the tolerability and pharmacokinetics of OAA in AD subjects. Six AD subjects received OAA 100<!--> <!-->mg capsules twice a day for one month. The intervention was well-tolerated. Blood level measurements following ingestion of a 100<!--> <!-->mg OAA capsule showed modest increases in OAA concentrations, but pharmacokinetic analyses were complicated by relatively high amounts of endogenous OAA. We conclude that OAA 100<!--> <!-->mg capsules twice per day for one month are safe in AD subjects but do not result in a consistent and clear increase in the OAA blood level, thus necessitating future clinical studies to evaluate higher doses.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2016.03.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9570938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation-associated changes in lipid composition and the organization of the erythrocyte membrane","authors":"Sip Dinkla ,&nbsp;Lucas T. van Eijk ,&nbsp;Beate Fuchs ,&nbsp;Jürgen Schiller ,&nbsp;Irma Joosten ,&nbsp;Roland Brock ,&nbsp;Peter Pickkers ,&nbsp;Giel J.C.G.M. Bosman","doi":"10.1016/j.bbacli.2016.03.007","DOIUrl":"10.1016/j.bbacli.2016.03.007","url":null,"abstract":"<div><h3>Background</h3><p>Reduced erythrocyte survival and deformability may contribute to the so-called anemia of inflammation observed in septic patients. Erythrocyte structure and function are affected by both the membrane lipid composition and the organization. We therefore aimed to determine whether these parameters are affected during systemic inflammation.</p></div><div><h3>Methods</h3><p>A sensitive matrix-assisted laser desorption and ionization time-of-flight mass spectrometric method was used to investigate the effect of plasma components of 10 patients with septic shock and of 10 healthy volunteers subjected to experimental endotoxemia on erythrocyte membrane lipid composition.</p></div><div><h3>Results</h3><p>Incubation of erythrocytes from healthy control donors with plasma from patients with septic shock resulted in membrane phosphatidylcholine hydrolysis into lysophosphatidylcholine (LPC). Plasma from volunteers undergoing experimental human endotoxemia did not induce LPC formation. The secretory phospholipase A₂ IIA concentration was enhanced up to 200-fold in plasma of septic patients and plasma from endotoxin-treated subjects, but did not correlate with the ability of these plasmas to generate LPC. Erythrocyte phosphatidylserine exposure increased up to two-fold during experimental endotoxemia.</p></div><div><h3>Conclusions</h3><p>Erythrocyte membrane lipid remodeling as reflected by LPC formation and/or PS exposure occurs during systemic inflammation in a secretory phospholipase A₂ IIA-independent manner.</p></div><div><h3>General significance</h3><p>Sepsis-associated inflammation induces a lipid remodeling of the erythrocyte membrane that is likely to affect erythrocyte function and survival, and that is not fully mimicked by experimental endotoxemia.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2016.03.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34565494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Up-regulation of the human-specific CHRFAM7A gene in inflammatory bowel disease","authors":"Andrew Baird ,&nbsp;Raul Coimbra ,&nbsp;Xitong Dang ,&nbsp;Brian P. Eliceiri ,&nbsp;Todd W. Costantini","doi":"10.1016/j.bbacli.2015.12.003","DOIUrl":"10.1016/j.bbacli.2015.12.003","url":null,"abstract":"<div><p>Background: The α7-subunit of the α7-nicotinic acetylcholine receptor (α7-nAChR) is an obligatory intermediate for the anti-inflammatory effects of the vagus nerve. But in humans, there exists a second gene called CHRFAM7A that encodes a dominant negative α7-nAChR inhibitor. Here, we investigated whether their expression was altered in inflammatory bowel disease (IBD) and colon cancer.</p><p>Methods: Quantitative RT-PCR measured gene expression of human α7-nAChR gene (CHRNA7), CHRFAM7A, TBC3D1, and actin in biopsies of normal large and small intestine, and compared to their expression in biopsies of ulcerative colitis, Crohn's disease, and colon cancer.</p><p>Results: qRT-PCR showed that CHRFAM7A and CHRNA7 gene expression was significantly (p<!--> <!-->&lt;<!--> <!-->.02) up-regulated in IBD (N<!--> <!-->=<!--> <!-->64). Gene expression was unchanged in colon cancer. Further analyses revealed that there were differences in ulcerative colitis and Crohn's Disease. Colon biopsies of ulcerative colitis (N<!--> <!-->=<!--> <!-->33) confirmed increased expression of CHRFAM7A and decreased in CHRNA7 expression (p<!--> <!-->&lt;<!--> <!-->0.001). Biopsies of Crohn's disease (N<!--> <!-->=<!--> <!-->31), however, showed only small changes in CHRFAM7A expression (p<!--> <!-->&lt;<!--> <!-->0.04) and no change in CHRNA7. When segregated by tissue source, both CHRFAM7A up-regulation (p<!--> <!-->&lt;<!--> <!-->0.02) and CHRNA7 down-regulation (p<!--> <!-->&lt;<!--> <!-->0.001) were measured in colon, but not in small intestine.</p><p>Conclusion: The human-specific CHRFAM7A gene is up-regulated, and its target, CHRNA7, down-regulated, in IBD. Differences between ulcerative colitis and Crohn's disease tie to location of disease.</p><p>Significance: The appearance of IBD in modern humans may be consequent to the emergence of CHRFAM7A, a human-specific α7-nAChR antagonist. CHRFAM7A could present a new, unrecognized target for development of IBD therapeutics.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2015.12.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54181192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycogen metabolism in humans","authors":"María M. Adeva-Andany,&nbsp;Manuel González-Lucán,&nbsp;Cristóbal Donapetry-García,&nbsp;Carlos Fernández-Fernández,&nbsp;Eva Ameneiros-Rodríguez","doi":"10.1016/j.bbacli.2016.02.001","DOIUrl":"10.1016/j.bbacli.2016.02.001","url":null,"abstract":"<div><p>In the human body, glycogen is a branched polymer of glucose stored mainly in the liver and the skeletal muscle that supplies glucose to the blood stream during fasting periods and to the muscle cells during muscle contraction. Glycogen has been identified in other tissues such as brain, heart, kidney, adipose tissue, and erythrocytes, but glycogen function in these tissues is mostly unknown. Glycogen synthesis requires a series of reactions that include glucose entrance into the cell through transporters, phosphorylation of glucose to glucose 6-phosphate, isomerization to glucose 1-phosphate, and formation of uridine 5ʹ-diphosphate-glucose, which is the direct glucose donor for glycogen synthesis. Glycogenin catalyzes the formation of a short glucose polymer that is extended by the action of glycogen synthase. Glycogen branching enzyme introduces branch points in the glycogen particle at even intervals. Laforin and malin are proteins involved in glycogen assembly but their specific function remains elusive in humans. Glycogen is accumulated in the liver primarily during the postprandial period and in the skeletal muscle predominantly after exercise. In the cytosol, glycogen breakdown or glycogenolysis is carried out by two enzymes, glycogen phosphorylase which releases glucose 1-phosphate from the linear chains of glycogen, and glycogen debranching enzyme which untangles the branch points. In the lysosomes, glycogen degradation is catalyzed by α-glucosidase. The glucose 6-phosphatase system catalyzes the dephosphorylation of glucose 6-phosphate to glucose, a necessary step for free glucose to leave the cell. Mutations in the genes encoding the enzymes involved in glycogen metabolism cause glycogen storage diseases.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2016.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54181224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression levels of estrogen receptor α mRNA in peripheral blood cells are an independent biomarker for postmenopausal osteoporosis","authors":"Chi-Wen Chou ,&nbsp;Tsay-I Chiang ,&nbsp;I-Chang Chang ,&nbsp;Chung-Hung Huang ,&nbsp;Ya-Wen Cheng","doi":"10.1016/j.bbacli.2016.03.001","DOIUrl":"10.1016/j.bbacli.2016.03.001","url":null,"abstract":"<div><h3>Background</h3><p>The up- and down-regulation of the osteoclastogenesis response depends on the estrogen/estrogen receptor (ER) signaling pathway. Previous reports have shown that the promoter hypermethylation and gene polymorphism of ERα are risks for menopausal osteoporosis. No previous study has evaluated the expression levels of ERα mRNA in menopausal osteoporosis using human subjects. We hypothesized that ERα mRNA expression may show less resistance to postmenopausal osteoporosis.</p></div><div><h3>Methods</h3><p>In this study, we enrolled 107 women older than 45<!--> <!-->years without menstruation and classified them into control, osteopenia, and osteoporosis groups depending on their T-scores. The ERα mRNA levels in peripheral blood cells (PBCs) were analyzed via quantitative real-time reverse-transcription polymerase chain reaction (QRT-PCR), and estrogen in the serum was detected via ELISA.</p></div><div><h3>Results</h3><p>ERα mRNA levels in PBCs had a negative correlation with age and a positive correlation with estrogen and BAP in the osteopenia and osteoporosis groups, but not in the control group. Additionally, multivariate analysis showed that older age (&gt;<!--> <!-->55<!--> <!-->years), and low ERα mRNA levels in PBLs (≦<!--> <!-->250.39 copies/μg DNA) were associated with an approximately 9.188-, and 31.25-fold risk of osteoporosis.</p></div><div><h3>Conclusion</h3><p>We conclude that ERα mRNA levels in PBLs could be used as an independent risk factor for postmenopausal osteoporosis.</p></div><div><h3>General significance</h3><p>Our findings suggested that ERα mRNA levels in PBLs may be more important than age and serum estrogen levels.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2016.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54181267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD)","authors":"Paul L. Wood ,&nbsp;Victoria A. Locke ,&nbsp;Patrick Herling ,&nbsp;Angelina Passaro ,&nbsp;Giovanni B. Vigna ,&nbsp;Stefano Volpato ,&nbsp;Giuseppe Valacchi ,&nbsp;Carlo Cervellati ,&nbsp;Giovanni Zuliani","doi":"10.1016/j.bbacli.2015.11.004","DOIUrl":"10.1016/j.bbacli.2015.11.004","url":null,"abstract":"<div><h3>Background</h3><p>Diverse research approaches support the concept that a clinical diagnosis of Late-Onset Alzheimer's Disease (LOAD) does not distinguish between subpopulations with differing neuropathologies, including dementia patients with amyloid deposition and dementia patients without amyloid deposition but with cortical thinning. Mild cognitive impairment (MCI) is generally considered the prodromal phase for LOAD, however, while a number of studies have attempted to define plasma biomarkers for the conversion of MCI to LOAD, these studies have not taken into account the heterogeneity of patient cohorts within a clinical phenotype.</p></div><div><h3>Methods</h3><p>Studies of MCI and LOAD in several laboratories have demonstrated decrements in ethanolamine plasmalogen levels in plasma and brain and increased levels of diacylglycerols in plasma and brain. To further extend these studies and to address the issue of heterogeneity in MCI and LOAD patient groups we investigated the levels of diacylglycerols and ethanolamine plasmalogens in larger cohorts of patients utilizing, high-resolution (0.2 to 2<!--> <!-->ppm mass error) mass spectrometry.</p></div><div><h3>Results</h3><p>For the first time, our lipidomics data clearly stratify both MCI and LOAD subjects into 3 different patient cohorts within each clinical diagnosis. These include i) patients with lower circulating ethanolamine plasmalogen levels; ii) patients with augmented plasma diacylglycerol levels; and iii) patients with neither of these lipid alterations.</p></div><div><h3>Conclusions</h3><p>These represent the first serum biochemical data to stratify MCI and LOAD patients, advancing efforts to biochemically define patient heterogeneity in cognitive disorders.</p></div><div><h3>General significance</h3><p>Lipidomics offers a new approach for identifying biomarkers and biological targets in cognitive disorders.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2015.11.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54180554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of single nucleotide polymorphisms implicate mTOR signalling in the development of new-onset diabetes after transplantation","authors":"S. Chand ,&nbsp;A.J. McKnight ,&nbsp;S. Shabir ,&nbsp;W. Chan ,&nbsp;J.A. McCaughan ,&nbsp;A.P. Maxwell ,&nbsp;L. Harper ,&nbsp;R. Borrows","doi":"10.1016/j.bbacli.2015.12.004","DOIUrl":"10.1016/j.bbacli.2015.12.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Despite excellent first year outcomes in kidney transplantation, there remain significant long-term complications related to new-onset diabetes after transplantation (NODAT). The purpose of this study was to validate the findings of previous investigations of candidate gene variants in patients undergoing a protocolised, contemporary immunosuppression regimen, using detailed serial biochemical testing to identify NODAT development.</p></div><div><h3>Methods</h3><p>One hundred twelve live and deceased donor renal transplant recipients were prospectively followed-up for NODAT onset, biochemical testing at days 7, 90, and 365 after transplantation. Sixty-eight patients were included after exclusion for non-white ethnicity and pre-transplant diabetes. Literature review to identify candidate gene variants was undertaken as described previously.</p></div><div><h3>Results</h3><p>Over 25% of patients developed NODAT. In an adjusted model for age, sex, BMI, and BMI change over 12<!--> <!-->months, five out of the studied 37 single nucleotide polymorphisms (SNPs) were significantly associated with NODAT: rs16936667:PRDM14 OR 10.57;95% CI 1.8–63.0;p<!--> <!-->=<!--> <!-->0.01, rs1801282:PPARG OR 8.5; 95% CI 1.4–52.7; p<!--> <!-->=<!--> <!-->0.02, rs8192678:PPARGC1A OR 0.26; 95% CI 0.08–0.91; p<!--> <!-->=<!--> <!-->0.03, rs2144908:HNF4A OR 7.0; 95% CI 1.1–45.0;p<!--> <!-->=<!--> <!-->0.04 and rs2340721:ATF6 OR 0.21; 95%CI 0.04–1.0; p<!--> <!-->=<!--> <!-->0.05.</p></div><div><h3>Conclusion</h3><p>This study represents a replication study of candidate SNPs associated with developing NODAT and implicates mTOR as the central regulator via altered insulin sensitivity, pancreatic β cell, and mitochondrial survival and dysfunction as evidenced by the five SNPs.</p></div><div><h3>General significance</h3><p></p><ul><li><span>1)</span><span><p>Highlights the importance of careful biochemical phenotyping with oral glucose tolerance tests to diagnose NODAT in reducing time to diagnosis and missed cases.</p></span></li><li><span>2)</span><span><p>This alters potential genotype:phenotype association.</p></span></li><li><span>3)</span><span><p>The replication study generates the hypothesis that mTOR signalling pathway may be involved in NODAT development.</p></span></li></ul></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2015.12.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54181199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No evidence of antibodies against GAD65 and other specific antigens in children with autism","authors":"Simran Kalra ,&nbsp;Peter D. Burbelo ,&nbsp;Ahmad Bayat ,&nbsp;Kathryn H. Ching ,&nbsp;Audrey Thurm ,&nbsp;Michael J. Iadarola ,&nbsp;Susan E. Swedo","doi":"10.1016/j.bbacli.2015.08.001","DOIUrl":"10.1016/j.bbacli.2015.08.001","url":null,"abstract":"<div><h3>Background</h3><p>The presence of autoantibodies has been proposed as evidence for a role of autoimmunity in autism. This report investigates the prevalence of autoantibodies in children with autism using the luciferase immunoprecipitation systems (LIPS) immunoassay technology. A panel of autoantibody targets against several known and candidate neurological autoantigens, autoimmune-associated autoantigens and viruses was employed.</p></div><div><h3>Methods</h3><p>Serological analysis was performed on typically developing children (n<!--> <!-->=<!--> <!-->55), developmentally delayed children without autism (n<!--> <!-->=<!--> <!-->24) and children diagnosed with autism (n<!--> <!-->=<!--> <!-->104). Autoantibodies were measured against glutamic acid decarboxylase-65 (GAD65), a CNS autoantigen proposed to be associated with autism and against Ro52, glial fibrillary acidic protein, tyrosine hydroxylase, aquaporin-4, and gamma-enolase, the mouse mammary tumor virus and the xenotropic murine leukemia virus. Antibody levels and seropositivity prevalence were analyzed for statistically significant differences between the three groups.</p></div><div><h3>Results</h3><p>The majority of the children (98%) were seronegative for all targets in the antigen panel. No GAD65 seropositive children were detected in the cohort. Several low level seropositive sera against several of the protein targets were identified in isolated children in each of the three groups, but there was no difference in prevalence.</p></div><div><h3>Conclusion</h3><p>Using this panel of antigens and a sensitive, robust assay, no evidence of unusual immunoreactivity was detected in children with autism, providing evidence against a role of autoimmunity against several previously implicated proteins in autism spectrum disorder pathogenesis.</p></div><div><h3>General significance</h3><p>The idea that autoantibodies represent an underlying cause or are biomarkers for autism pathophysiology is not supported by this report.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2015.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34068775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}